Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EBT (2022 - 2025)

Historic EBT for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$34.4 million.

  • Century Therapeutics' EBT fell 1020.68% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.7 million, marking a year-over-year increase of 8110.86%. This contributed to the annual value of -$124.8 million for FY2024, which is 743.07% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' EBT is -$34.4 million, which was down 1020.68% from -$32.5 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' EBT registered a high of $76.6 million during Q1 2025, and its lowest value of -$40.3 million during Q4 2023.
  • Its 4-year average for EBT is -$25.4 million, with a median of -$31.6 million in 2022.
  • Per our database at Business Quant, Century Therapeutics' EBT crashed by 2722.59% in 2023 and then skyrocketed by 37283.42% in 2025.
  • Over the past 4 years, Century Therapeutics' EBT (Quarter) stood at -$31.6 million in 2022, then fell by 27.23% to -$40.3 million in 2023, then increased by 14.83% to -$34.3 million in 2024, then dropped by 0.36% to -$34.4 million in 2025.
  • Its last three reported values are -$34.4 million in Q3 2025, -$32.5 million for Q2 2025, and $76.6 million during Q1 2025.